Market capitalization | JPY1.61t |
Enterprise Value | JPY1.51t |
P/E (TTM) P/E ratio | 49.42 |
EV/FCF (TTM) EV/FCF | 61.89 |
EV/Sales (TTM) EV/Sales | 2.06 |
P/S ratio (TTM) P/S ratio | 2.19 |
P/B ratio (TTM) P/B ratio | 1.80 |
Dividend yield | 2.82% |
Last dividend (FY25) | JPY160.00 |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
16 Analysts have issued a Eisai forecast:
16 Analysts have issued a Eisai forecast:
Jun '24 | |
Current assets | 733,222 733,222 |
Fixed assets | 687,025 687,025 |
Total Assets | 1,420,247 1,420,247 |
Jun '24 | |
Equity | 919,696 919,696 |
Debt capital | 500,551 500,551 |
Total Capital | 1,420,247 1,420,247 |
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Head office | Japan |
CEO | Haruo Naito |
Employees | 11,067 |
Founded | 1936 |
Website | www.eisai.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.